Intellia Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 526
- Market Cap
- $2.3B
- Website
- http://www.intelliatx.com
- Introduction
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Biotechnology Market Size to Reach USD 5.68 Trillion by 2033
The global biotechnology market, valued at USD 1.54 Trillion in 2023, is projected to reach USD 5.68 Trillion by 2033, growing at a CAGR of 13.95%. Growth is driven by government support, personalized medicine, COVID-19 vaccine development, agricultural biotech applications, and advancements in gene editing and synthetic biology. North America leads the market, while Asia Pacific is expected to grow the fastest.
CRISPR Clinical Trials: A 2024 Update
CRISPR-based therapies have achieved a milestone with the approval of Casgevy for sickle cell disease and beta thalassemia. Despite financial pressures and clinical trial challenges, CRISPR's potential in treating various diseases, including cancers and genetic disorders, is expanding. Innovations in delivery methods and regulatory approaches are key to future advancements.
Intellia to lay off staff, cut some early research
Intellia Therapeutics, a CRISPR specialist, will lay off 15% of its workforce, pausing some early-stage research to focus on its advanced drug candidate, NTLA-2001, for ATTR amyloidosis. Despite setbacks, including a discontinued partnership with Novartis, Intellia continues Phase 3 trials for NTLA-2001 and explores gene editing treatments with Regeneron.
Sickle Cell Disease Market Size, Growth, Trends, Report 2032
The Sickle Cell Disease Market, valued at 3.54 USD Billion in 2022, is projected to grow to 12.56 USD Billion by 2032, with a CAGR of 13.5%. Growth is driven by rising prevalence, advancements in gene therapy, and increased awareness. Key trends include precision medicine, digital health technologies, and patient-centered care, with significant opportunities in gene editing and targeted therapies.
© Copyright 2025. All Rights Reserved by MedPath